▲ 0.59%
prev close
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
Congressional Trades
3
All tracked trades
Members Trading
3
Unique members
Net Activity
-1
1 buys · 2 sells
Members Who Traded This Stock
3 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-11-12 | VCYTVeracyte, Inc. - Common Stock | Sell | $1,001 - $15,000 | 108d ago | — | |
| 2023-10-16 | VCYTVeracyte, Inc. - Common Stock | Buy | $1,001 - $15,000 | 873d ago | — | |
| 2023-04-10 | VCYTVeracyte, Inc. - Common Stock | Sell | $1,001 - $15,000 | 1049d ago | — |
2025-11-12
Gilbert Cisneros
VCYT
Amount
$1,001 - $15,000
Filed
108d ago
2023-10-16
Josh Gottheimer
VCYT
Amount
$1,001 - $15,000
Filed
873d ago
2023-04-10
Daniel Goldman
VCYT
Amount
$1,001 - $15,000
Filed
1049d ago
Recent News
Powered by Polygon.io
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide
Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive
Should You Continue to Retain PODD Stock in Your Portfolio Now?
Globus Medical (GMED) Global Sales, Innovation Aid Growth - Zacks Investment Research
Trade Timeline
Congressional activity, newest first
Gilbert Cisneros
2025-11-12 · Sale
$1,001 - $15,000
Josh Gottheimer
2023-10-16 · Purchase
$1,001 - $15,000
Daniel Goldman
2023-04-10 · Sale
$1,001 - $15,000